Premium
Scheduling process at DEA ‐ the example of cannabidiol
Author(s) -
Ghozland Sandy G,
Tolliver James M,
Carr Susan M,
Sannerud Christine A
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.711.1
Subject(s) - cannabidiol , abuse liability , stimulus control , substance abuse , drug , medicine , pharmacology , psychology , psychiatry , cannabis , nicotine
DEA collects and reviews scientific, medical and other data on substances to determine their abuse potential and placement into the Controlled Substances Act (CSA). The scientific data reviewed includes in vitro pharmacology and pre‐clinical abuse liability studies. In particular, data on discriminative stimulus effects and rewarding properties is essential to determining whether a substance belongs in a class of drugs already scheduled, and to predict its abuse potential. The medical data reviewed includes laboratory‐controlled clinical studies. Databases and surveys on drug abuse patterns, illicit trafficking and seizures provide DEA with valuable information on the actual abuse of a drug and its consequences on health, public health and public safety. Cannabidiol (CBD) is one of many cannabinoids present in marijuana, and as such is in schedule I of the CSA. DEA is currently conducting a scientific review of CBD to elucidate its pharmacology and abuse liability and to identify gaps in the published literature.